Continuous regional arterial infusion therapy with gabexate mesilate for severe acute pancreatitis

World Journal of Gastroenterology

Volumn 14, Issue 41, 2008, Pages 6382-6387

  Ino, Yoshifumi ^a,c   Arita, Yoshiyuki ^a   Akashi, Tetsuro ^b   Kimura, Toshinari ^c   Igarashi, Hisato ^a   Oono, Takamasa ^a   Furukawa, Masayuki ^a,c   Kawabe, Ken ^a   Ogoshi, Keiichiro ^d   Oochi, Jiro ^e   Miyahara, Toshihiko ^f   Takayanagi, Ryoichi ^a   Ito, Tetsuhide ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b SAISEIKAI FUKUOKA GENERAL HOSPITAL   (Japan)

^c Nakabaru Hospital   (Japan)

^d FUKUOKA HIGASHI MEDICAL CENTER   (Japan)

^e NATIONAL KYUSHU CANCER CENTER   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

Author keywords

Antibiotics; Arterial infusion; Gabexate mesilate; Severe acute pancreatitis

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; CARBAPENEM; GABEXATE MESILATE; INTERLEUKIN 10; INTERLEUKIN 6; PROTEINASE INHIBITOR; ANTIINFECTIVE AGENT; AUTACOID; GABEXATE; IL6 PROTEIN, HUMAN; SERINE PROTEINASE INHIBITOR;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; MALE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT DURATION; TREATMENT OUTCOME; ACUTE DISEASE; AGED; BLOOD; DRUG COMBINATION; HOSPITALIZATION; IMMUNOLOGY; INTRAARTERIAL DRUG ADMINISTRATION; JAPAN; LENGTH OF STAY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PANCREATITIS;

ABDOMINAL PAIN; ACUTE DISEASE; ADULT; AGED; ANTI-BACTERIAL AGENTS; C-REACTIVE PROTEIN; DRUG THERAPY, COMBINATION; FEMALE; GABEXATE; HUMANS; INFLAMMATION MEDIATORS; INFUSIONS, INTRA-ARTERIAL; INTERLEUKIN-10; INTERLEUKIN-6; JAPAN; LENGTH OF STAY; MALE; MIDDLE AGED; PANCREATITIS; PROSPECTIVE STUDIES; SERINE PROTEINASE INHIBITORS; SEVERITY OF ILLNESS INDEX; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME;

EID: 63449140185     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.6382     Document Type: Article

References (23)

1. Bradley EL 3rd. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch Surg 1993; 128: 586-590
2. Al Mofleh IA. Severe acute pancreatitis: pathogenetic aspects and prognostic factors. World J Gastroenterol 2008; 14: 675-684
3. Takeda K, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, Sekimoto M, Hirota M, Kimura Y, Isaji S, Koizumi M, Otsuki M, Matsuno S. JPN Guidelines for the management of acute pancreatitis: medical management of acute pancreatitis. J Hepatobiliary Pancreat Surg 2006; 13: 42-47
4. Otsuki M, Hirota M, Arata S, Koizumi M, Kawa S, Kamisawa T, Takeda K, Mayumi T, Kitagawa M, Ito T, Inui K, Shimosegawa T, Tanaka S, Kataoka K, Saisho H, Okazaki K, Kuroda Y, Sawabu N, Takeyama Y. Consensus of primary care in acute pancreatitis in Japan. World J Gastroenterol 2006; 12: 3314-3323
5. Koizumi M, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, Sekimoto M, Hirota M, Kimura Y, Takeda K, Isaji S, Otsuki M, Matsuno S. JPN Guidelines for the management of acute pancreatitis: diagnostic criteria for acute pancreatitis. J Hepatobiliary Pancreat Surg 2006; 13: 25-32
6. Ogawa M, Hirota M, Hayakawa T, Matsuno S, Watanabe S, Atomi Y, Otsuki M, Kashima K, Koizumi M, Harada H, Yamamoto M, Nishimori I. Development and use of a new staging system for severe acute pancreatitis based on a nationwide survey in Japan. Pancreas 2002; 25: 325-330
7. Valderrama R, Perez-Mateo M, Navarro S, Vazquez N, Sanjose L, Adrian MJ, Estruch J. Multicenter double-blind trial of gabexate mesylate (FOY) in unselected patients with acute pancreatitis. Digestion 1992; 51: 65-70
8. Yang CY, Chang-Chien CS, Liaw YF. Controlled trial of protease inhibitor gabexelate mesilate (FOY) in the treatment of acute pancreatitis. Pancreas 1987; 2: 698-700
9. Buchler M, Malfertheiner P, Uhl W, Scholmerich J, Stockmann F, Adler G, Gaus W, Rolle K, Beger HG. Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group. Gastroenterology 1993; 104: 1165-1170
10. Messori A, Rampazzo R, Scroccaro G, Olivato R, Bassi C, Falconi M, Pederzoli P, Martini N. Effectiveness of gabexate mesilate in acute pancreatitis. A metaanalysis. Dig Dis Sci 1995; 40: 734-738
11. Chen HM, Chen JC, Hwang TL, Jan YY, Chen MF. Prospective and randomized study of gabexate mesilate for the treatment of severe acute pancreatitis with organ dysfunction. Hepatogastroenterology 2000; 47: 1147-1150
12. Inoue K, Hirota M, Kimura Y, Kuwata K, Ohmuraya M, Ogawa M. Further evidence for endothelin as an important mediator of pancreatic and intestinal ischemia in severe acute pancreatitis. Pancreas 2003; 26: 218-223
13. Takeda K, Mikami Y, Fukuyama S, Egawa S, Sunamura M, Ishibashi T, Sato A, Masamune A, Matsuno S. Pancreatic ischemia associated with vasospasm in the early phase of human acute necrotizing pancreatitis. Pancreas 2005; 30: 40-49
14. Takeda K, Matsuno S, Sunamura M, Kakugawa Y. Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. Am J Surg 1996; 171: 394-398
15. Anai H, Sakaguchi H, Uchida H, Matsuo N, Tanaka T, Yoshioka T, Ohishi H, Murao Y, Miyamoto S. Continuous arterial infusion therapy for severe acute pancreatitis: correlation between CT arteriography and therapeutic effect. J Vasc Interv Radiol 1999; 10: 1335-1342
16. Imaizumi H, Kida M, Nishimaki H, Okuno J, Kataoka Y, Kida Y, Soma K, Saigenji K. Efficacy of continuous regional arterial infusion of a protease inhibitor and antibiotic for severe acute pancreatitis in patients admitted to an intensive care unit. Pancreas 2004; 28: 369-373
17. Takeda K, Matsuno S, Ogawa M, Watanabe S, Atomi Y. Continuous regional arterial infusion (CRAI) therapy reduces the mortality rate of acute necrotizing pancreatitis: results of a cooperative survey in Japan. J Hepatobiliary Pancreat Surg 2001; 8: 216-220
18. Kakugawa Y, Takeda K, Sunamura M, Kawaguchi S, Kobari M, Matsuno S. [Effect of continuous arterial infusion of protease inhibitor on experimental acute pancreatitis induced by closed duodenal loop obstruction] Nippon Shokakibyo Gakkai Zasshi 1990; 87: 1444-1450
19. Satoh H, Harada M, Tashiro S, Shiroya T, Imawaka H, Machii K. The effect of continuous arterial infusion of gabexate mesilate (FOY-007) on experimental acute pancreatitis. J Med Invest 2004; 51: 186-193
20. Pederzoli P, Cavallini G, Falconi M, Bassi C. Gabexate mesilate vs aprotinin in human acute pancreatitis (GA. ME.P.A.). A prospective, randomized, double-blind multicenter study. Int J Pancreatol 1993; 14: 117-124
21. Takahashi Y, Shibata A. The comparative study of nafamostat mesilate (FUT-175), gabexate mesilate (FOY) and heparin on anticoagulant and antifibrinolytic action. Jpn J Clin Exp Med 1988; 65: 127-134
22. Muto S, Imai M, Asano Y. Effect of nafamostat mesilate on Na+ and K+ transport properties in the rabbit cortical collecting duct. Br J Pharmacol 1993; 109: 673-678
23. Ohmoto K, Yamamoto S. Serum interleukin-6 and interleukin-10 in patients with acute pancreatitis: clinical implications. Hepatogastroenterology 2005; 52: 990-994